ライフサイエンスコーパス: calpain inhibitor

1 ase in expression of calpastatin (endogenous calpain inhibitor).

2 mined at high concentrations in vitro by the calpain inhibitor.

3 ng apoptosis was significantly retarded by a calpain inhibitor.

4 also significantly increased (P < 0.05) with calpain inhibitor.

5 vented by calpastatin, a naturally occurring calpain inhibitor.

6 overexpression of calpastatin, an endogenous calpain inhibitor.

7 select for resistance to this cell-permeant calpain inhibitor.

8 d 4) mechanical ventilation with a selective calpain inhibitor.

9 ceptors; both effects were also blocked by a calpain inhibitor.

10 spase inhibitor but not by the proteosome or calpain inhibitor.

11 slices was prevented by a membrane-permeable calpain inhibitor.

12 agmatic levels of calpastatin, an endogenous calpain inhibitor.

13 e intracellular Ca2+ chelator but not by the calpain inhibitor.

14 pha processing was blocked by proteasome and calpain inhibitors.

15 d preservation in the presence or absence of calpain inhibitors.

16 gn of cyclic peptides and peptidomimetics as calpain inhibitors.

17 Cleavage was inhibited by calpain inhibitors.

18 ely proteasome-independent, but sensitive to calpain inhibitors.

19 respectively) was limited with any of these calpain inhibitors.

20 eolysis occurs in a manner sensitive only to calpain inhibitors.

21 xide 1h (IC50 = 0.35 microM) are also potent calpain inhibitors.

22 ased by about 50%, an effect also blocked by calpain inhibitors.

23 ctivity as well as evaluating the effects of calpain inhibitors.

24 egulated by distinct doses of proteasome and calpain inhibitors.

25 nto smaller fragments was totally blocked by calpain inhibitors.

26 Activation is prevented by calpain inhibitors.

27 n be inhibited by calcium chelators and some calpain inhibitors.

28 D1 protein that was completely reversible by calpain inhibitors.

29 on, but this inhibition could be reversed by calpain inhibitors.

30 to classic electrophilic "warheads" in known calpain inhibitors.

31 st PPADS, the calcium chelator BAPTA-AM, and calpain inhibitors.

32 tive form required Ca(2+) and was blocked by calpain inhibitors.

33 lpain substrate, was modulated by Ca(2+) and calpain inhibitors.

34 dent on calpains, such that it is blocked by calpain inhibitors.

35 on, which was completely blocked by MAPK and calpain inhibitors.

36 ketoesters was synthesized and studied as mu-calpain inhibitors.

37 tenuated by buffering [Ca2+]i and blocked by calpain inhibitors.

38 rons, which was largely blocked by selective calpain inhibitors.

39 rs when added to osteoclasts pretreated with calpain inhibitors.

40 ells by up-regulating endogenous caspase and calpain inhibitors.

41 The calpain inhibitor (2)-3-(4-iodophenyl)-2-mercapto-2-prop

42 nous protease which is inhibited by specific calpain inhibitors; 3.

43 The calpain inhibitor A-705253 (3-10 mg/kg) was tested in a

44 generation of p29 was Ca(2+)-dependent, and calpain inhibitors abolished p29 production.

45 Addition of calpain inhibitors after BDNF or TEA treatment maintaine

46 ies was substantially delayed by addition of calpain inhibitors after sublethal excitotoxic exposure.

47 n this study, we evaluated the effect of the calpain inhibitor AK295 [Z-Leu-aminobutyric acid-CONH(CH

48 of calpains with the peptide alpha-ketoamide calpain inhibitor AK295 can reduce the clinical and path

49 Pretreatment with both the calpain inhibitor ALLN (N-acetyl-Leu-Leu-norleucinal) an

50 the cysteine protease inhibitor E-64 or the calpain inhibitor ALLN (N-acetyl-leucyl-leucyl-norleucin

51 Calpain inhibitor ALLN induced VEGFR2 activation, which

52 ion-induced immobilization is prevented by a calpain inhibitor and by an allosteric LFA-1 inhibitor.

53 l calcium sensor-1 (NCS1), or treatment with calpain inhibitor and ibudilast reversed deficits observ

54 Data suggests CYGAK may be a P' calpain inhibitor and may achieve its specificity throug

55 (CYGAK)(2) is the first P' specific calpain inhibitor and will be a valuable tool to prevent

56 rption in a manner similar to the effects of calpain inhibitors and had no further effect on these pa

57 d breast cancer cells that was reversible by calpain inhibitors and not by phenylmethylsulfonyl fluor

58 romolar range, rivaling other peptidomimetic calpain inhibitors and presenting an improved selectivit

59 sults indicate that MP acts as a proteinase (calpain) inhibitor and define a new mechanism for its ac

60 The mRNA levels of calpastatin (endogenous calpain inhibitor) and beta-actin (house-keeping) genes

61 bitors (peptidomimetic and natural product), calpain inhibitors, and anti-PgPM4 monoclonal antibodies

62 xazolyl-propionic acid receptor antagonists, calpain inhibitors, and cyclosporine A analogues.

63 rs, including three GSK3beta inhibitors, two calpain inhibitors, and one adenylyl cyclase activator,

64 h is sensitive to wortmannin (IC50 7 nM) and calpain inhibitors, and the phosphorylation of PtdIns3P

65 om P3 rats were used to test the efficacy of calpain inhibitors as otoprotective molecules.

66 Greater sensitivity of HT-29 cells to a calpain inhibitor, as measured by IL-8 secretion, sugges

67 e positive CD4(+) thymocytes, not only did a calpain inhibitor augment CD3-induced proliferation, but

68 protease inhibitor, and the highly specific calpain inhibitor BDA-410 restored normal synaptic funct

69 raperitoneal administration of the selective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 m

70 Moreover, calpain inhibitors blocked the ischaemia-induced depress

71 Calpain inhibitors blocked these changes.

72 e receptor into the cell culture medium, and calpain inhibitors blocked this effect.

73 of C6 cells with calpeptin (a cell-permeable calpain inhibitor) blocked calpain overexpression, MAG d

74 Calpeptin, a cell-permeable calpain inhibitor, blocked both Erk1,2 activation and ne

75 etreatment of Jurkat cells with calpeptin, a calpain inhibitor, blocked PTP1B cleavage and inhibited

76 lencing; however, it could be prevented with calpain inhibitors, calcium-chelating agents, calpain kn

77 rt-term (4-h) exposure to the cell-permeable calpain inhibitors calpain inhibitor II and E-64-d incre

78 cular endothelial cell monolayers exposed to calpain inhibitors (calpain inhibitor III and calpastati

79 Three calpain inhibitors, calpain inhibitor I, MDL-28170, and

80 In contrast to proteasomal inhibitors, the calpain inhibitor calpastatin and the lysosomal inhibito

81 Transient expression of the specific calpain inhibitor calpastatin blocked the loss of p107 p

82 Transient expression of the calpain inhibitor calpastatin increased cyclin D1 protei

83 Overexpression of the calpain inhibitor calpastatin or eIF4G1 resulted in incr

84 yR antagonists ryanodine and dantrolene, the calpain inhibitor calpastatin, and by a specific inhibit

85 calpeptin, overexpression of the endogenous calpain inhibitor calpastatin, or gene silencing of calp

86 of either m- or mu-calpain or the endogenous calpain inhibitor calpastatin.

87 proteases and down-regulated the endogenous calpain inhibitor calpastatin.

88 regulated the caspase inhibitor FLIP and the calpain inhibitor calpastatin.

89 lled by a marked depletion of the endogenous calpain inhibitor, calpastatin (CAST), from AD neurons,

90 es showed increased levels of the endogenous calpain inhibitor, calpastatin (CAST).

91 on, whereas overexpression of the endogenous calpain inhibitor, calpastatin, attenuated Ox-LDL-induce

92 alpains and overexpression of the endogenous calpain inhibitor, calpastatin, prevent the production o

93 lt of the marked depletion of the endogenous calpain inhibitor, calpastatin.

94 lation-induced degradation of the endogenous calpain inhibitor, calpastatin.

95 rn indicative of calpain activation, and the calpain inhibitor calpeptin abrogated SAHA-induced cell

96 Indeed, the calpain inhibitor calpeptin and the removal of the calpa

97 Pretreatment with the calpain inhibitor calpeptin blocked calpain activation a

98 retreatment of HL-60 cells with the specific calpain inhibitor calpeptin effectively blocked both dru

99 Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF

100 The calpain inhibitor calpeptin increased WASP levels in act

101 ected with AdPCSK9 and then treated with the calpain inhibitor calpeptin to inhibit FLNA cleavage.

102 Interestingly, treatment with the calpain inhibitor calpeptin, overexpression of the endog

103 um-dependent and was blocked by the specific calpain inhibitor calpeptin.

104 died possible neuroprotective effects of the calpain inhibitors calpeptin and calpain inhibitor V.

105 ffect was much less than that exerted by the calpain inhibitors calpeptin and/or E64-d.

106 The peptidyl calpain inhibitors calpeptin, MDL 28,170 (MDL) and E64d

107 received daily intraperitoneal injections of calpain inhibitor (calpeptin) or vehicle from day 1 unti

108 d by the PI3K inhibitor, wortmannin, and the calpain inhibitor, calpeptin, constituting the first evi

109 se hamster ovary cells were decreased by the calpain inhibitor, calpeptin, or the highly specific cal

110 In addition, preincubation with the calpain inhibitor, calpeptin, suppressed the accumulatio

111 1 subunits were significantly reduced by the calpain inhibitor, calpeptin.

112 d from this animal model of SCI suggest that calpain inhibitor can provide neuroprotection in patient

113 ssive depletion; we show here that selective calpain inhibitors can block this step, which suggests t

114 Calpain inhibitors can protect against necrotic neuronal

115 hesions or stress fibers) in the presence of calpain inhibitors; cells expressing constitutively acti

116 were studied; subgroups were treated with a calpain inhibitor (CI).

117 ing the EGFP-ataxin-3-84Q zebrafish with the calpain inhibitor compound calpeptin decreased levels of

118 und that treating the MJD zebrafish with the calpain inhibitor compound calpeptin produces complete r

119 findings indicate that Sarm1 and/or specific calpain inhibitors could be developed to prevent cisplat

120 Previous work using calpain inhibitor CYLA in our laboratory showed signific

121 cell receptor-stimulated murine thymocytes, calpain inhibitors decreased cleavage of gammac.

122 cTnT-ND in myocardial ischemia reperfusion, calpain inhibitors decreased the level of cTnT-ND in Tri

123 Experimental treatments with caspase 3 or calpain inhibitors demonstrated that PV IgGs induced aca

124 ddition, I-benzyl-CH=C(SH)COOH (PD150606), a calpain inhibitor directed toward the calcium binding si

125 Calpain inhibitors disrupted the podosome belt, blocked

126 T3, prostate, and breast cancer cells with a calpain inhibitor dramatically increased the half-life o

127 pain activity which can be attenuated by the calpain inhibitor E-64-d.

128 ydrazine, KCl, quinine, merocyanine 540, the calpain inhibitor E-64d, and the scramblase inhibitor R5

129 pan-caspase inhibitor z-VAD-fmk, but not the calpain inhibitor E-64d, prevents Bid cleavage, Bax conf

130 The calpain inhibitor E64-d or the lysosomal protease inhibi

131 he absence of calcium and in the presence of calpain inhibitors (E64c, PD 150606 and calpastatin).

132 Calpain inhibitors elicited effects at concentrations of

133 knowledge, this study is the first to use a calpain inhibitor following brain trauma and suggests th

134 pase-2 down-regulation by rottlerin, whereas calpain inhibitor had no effect.

135 pastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, wh

136 dysfunction, all of which were attenuated by calpain inhibitor I (10 mg/kg i.p.), administered 30 min

137 s completely inhibited by preincubation with calpain inhibitor I (N-acetyl-leucyl-leucyl-norleucinal

138 h ubiquitin-dependent proteasome inhibitors: calpain inhibitor I and lactacystin each prevented this

139 bited by the addition of protease inhibitors calpain inhibitor I and N-tosyl-phechloromethyl ketone a

140 by pharmacological inhibitors (calpeptin and calpain inhibitor I and PD98059, respectively) for EGF-i

141 muscle cells (activated with endotoxin) with calpain inhibitor I attenuated the binding of activated

142 whereas complete inhibition is observed with calpain inhibitor I but not with the proteasome inhibito

143 Here we investigate the effects of calpain inhibitor I on the organ injury (kidney, liver,

144 As anticipated, pretreatment with calpain inhibitor I prevented the proteolytic degradatio

145 rovide evidence that the mechanisms by which calpain inhibitor I reduces the circulatory failure as w

146 ain inhibitors N-acetyl-leu-leu-norleucinal (calpain inhibitor I) and carbenzoxy-val-phe-H (MDL 28,17

147 and N-acetyl-leucinyl-leucinyl-norleucinal (calpain inhibitor I) were found to inhibit the CL activi

148 Our results indicate that calpain inhibitor I, calpain inhibitor II, and leupeptin

149 addition of protease inhibitors, leupeptin, calpain inhibitor I, E-64, or pepstatin (0.5 mM each) to

150 Sulfasalazine and calpain inhibitor I, inhibitors of NF-kappaB activation,

151 The cell permeant agent, calpain inhibitor I, limited EGF-induced motility and de

152 Three calpain inhibitors, calpain inhibitor I, MDL-28170, and PD150606, but not th

153 s as nifedipine, verapamil and diltiazem, by calpain inhibitor I, or by the intracellular calcium che

154 Lactacystin and calpain inhibitor I, specific inhibitors of the 26S prot

155 which could be blocked by pretreatment with calpain inhibitor I.

156 e activity, in NIH3T3 cells was inhibited by calpain inhibitors I and II or the p38 MAP kinase inhibi

157 ddition of the calpain inhibitors MDL28,170, calpain inhibitors I and II, and leupeptin (all 1-100 mi

158 in YY1 protein levels could be prevented by calpain inhibitor II and calpeptin.

159 scle strips and adipocytes, exposure to both calpain inhibitor II and E-64-d reduced insulin-mediated

160 Calpain inhibitor II similarly blocked formation of the

161 y TCDD, whereas the protease inhibitors EST, calpain inhibitor II, and chloroquine do not affect this

162 r results indicate that calpain inhibitor I, calpain inhibitor II, and leupeptin all provided signifi

163 viral activity, including GC376, boceprevir, calpain inhibitors II, and XII, with each containing a r

164 Calpain inhibition via calpain inhibitor III and calpastatin decreased IL-1beta

165 ll monolayers exposed to calpain inhibitors (calpain inhibitor III and calpastatin) or transfected wi

166 eridine propranol and were partly blocked by calpain inhibitor III but were not affected by the NR2A-

167 murine L cells, treatment with calpeptin or calpain inhibitor III increased Abeta42, but not Abeta40

168 and Abeta42 prompted us to determine how the calpain inhibitor III MDL 28170 influences these three c

169 inhibitor of calcium/calmodulin kinase, and calpain inhibitor III, a calpain inhibitor, inhibited NM

170 ibiting the activation of calpain by a novel calpain inhibitor in aged 3xTgAD mice with well-establis

171 overexpress human calpastatin, an endogenous calpain inhibitor, in skeletal muscle were produced.

172 nase (CaMK) type IV, which was attenuated by calpain inhibitors, in GCs supplemented with 20 mm KCl.

173 Cell-permeable calpain inhibitors, including calpastatin and calpeptin,

174 Studies using specific caspase or calpain inhibitors indicate that the pattern of spectrin

175 Studies with a selective membrane permeable calpain inhibitor indicated that tTG is likely to be an

176 illomavirus E6 protein was unaffected by the calpain inhibitor, indicating that the stabilization did

177 Calpain inhibitors inhibited the cleavage of the beta3 c

178 modulin kinase, and calpain inhibitor III, a calpain inhibitor, inhibited NMDA-induced potentiation a

179 , indicating that inhibition of apoptosis by calpain inhibitors is independent of effects on viral re

180 apoptosis, indicating that the effect of the calpain inhibitors is not due to cross-inhibition of lys

181 nsulin secretion with short-term exposure to calpain inhibitors is not mediated by increased response

182 vage is inhibited by calpeptin, calpastatin, calpain inhibitor IV, and E-64d, but not by caspase 3 in

183 of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by t

184 These calpain inhibitors limited epidermal growth factor-induc

185 Calpain inhibitors may therefore be useful therapeutical

186 hich was attenuated by pretreatment with the calpain inhibitor MDL-28170 or by transgenic overexpress

187 These effects were blocked by the calpain inhibitor MDL-28170.

188 uct immunoreactivity could be blocked by the calpain inhibitor MDL28,170 and appeared in neuronal cel

189 Addition of the calpain inhibitors MDL28,170, calpain inhibitors I and I

190 n of Akt in ASMCs, which were blocked by the calpain inhibitor MDL28170.

191 The calpain inhibitor, MDL28170, significantly improved the

192 y of globupain led to the discovery that the calpain inhibitors MG101 and leupeptin inactivate globup

193 Here, we report that treatment with the calpain inhibitor N-[N-(N-acetyl-l-leucyl)-l-leucyl]-l-n

194 uced NF-kappaB activation was blocked by the calpain inhibitor N-Ac-Leu-Leu-norleucinal, suggesting t

195 Exposure of preadipocytes to the calpain inhibitor N-acetyl-Leu-Leu-norleucinal or overex

196 The calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal (AL

197 Calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal blo

198 Calpain inhibitors N-acetyl-leu-leu-norleucinal (ALLN) a

199 We found that the calpain inhibitors N-acetyl-leu-leu-norleucinal (calpain

200 ocarbamate), Ca(2+) chelator (BAPTA-AM), and calpain inhibitor (N-acetyl-Leu-Leu-Met-H).

201 lator, 3,4,5-trimethoxybenzoic acid, and the calpain inhibitor, N-acetyl-Leu-Leu-norleucinal, both bl

202 The calpain inhibitor, N-acetyl-leucyl-leucyl-methional, or

203 Surprisingly, calpeptin was the only calpain inhibitor of several tested with the ability to

204 ressing calpastatin, the specific endogenous calpain inhibitor, on the activity of the two proteolyti

205 Studies utilizing Calpain inhibitors or Calpain-deficient cells confirm th

206 S activity in HAECs, which were prevented by calpain inhibitors or mu-calpsiRNA.

207 k but were blocked fully by the irreversible calpain inhibitor PD150606.

208 microM), a potent calmodulin inhibitor, and calpain inhibitor peptide (CIP, 10 microM) protected neu

209 Treating diabetic mice with a calpain inhibitor prevented loss of platelet dicer as we

210 The calpain inhibitor prevented proteoglycan loss, but the p

211 Calpastatin, a specific calpain inhibitor prevented the effects of calpain I on

212 Calpain inhibitors prevented cleavage of Bid as well as

213 Cell-permeable calpain inhibitors prevented E-cad(100) induction by ion

214 lines were established that overexpress the calpain inhibitor protein, calpastatin, under control of

215 inhibitor, calpeptin, or the highly specific calpain inhibitor protein, calpastatin.

216 Calpain inhibitors reduced IL-1alpha release and MCP-1 u

217 ated AR, and treatment of these cells with a calpain inhibitor reduces truncated AR expression.

218 Calpain inhibitors rescued HHcy- and HHcy/HG-induced ED

219 calpain-knockout mice or rats treated with a calpain inhibitor resulted in prevention of increased ri

220 Co-treatment with calpain inhibitors resulted in preservation of titin, re

221 Finally, the use of isoform-selective calpain inhibitors revealed that calpain-2 was involved

222 In contrast, animals pretreated with the calpain inhibitor showed minimal evidence of apoptosis.

223 Calpain inhibitor SJA6017 may have potential for testing

224 e-3 and could be completely inhibited by the calpain inhibitor SJA6017, implicating both calpain and

225 ted calpain, and reduction of cell damage by calpain inhibitor SJA6017.

226 he retinal cells treated with 10 and 100 muM calpain inhibitor SNJ-1945.

227 Calpain inhibitors suppressed NF-kappaB activation via i

228 ketophosphonates 1c,e,f are much less potent calpain inhibitors than dimethyl alpha-ketophosphonate 1

229 Both aLLN and PD150606, a specific calpain inhibitor that interacts with the calcium-bindin

230 In the presence of a calpain inhibitor, the apoptosis-inducing activity of PS

231 Intraperitoneal injection of a short term calpain inhibitor to timed pregnant female mice abrogate

232 otoxins (e.g., cisplatin, CDDP), the role of calpain inhibitors under these conditions was examined i

233 ects of the calpain inhibitors calpeptin and calpain inhibitor V.

234 vo treatment with the calpastatin peptide, a calpain inhibitor, was strongly neuroprotective in mice

235 Using proteasome and calpain inhibitors, we determined that the basal activit

236 These beneficial effects of the calpain inhibitors were associated with restoration of n

237 4 as a lead, three successive generations of calpain inhibitors were developed using computationally

238 Rac or Rho, respectively, occurred even when calpain inhibitors were present.

239 ations of calpastatin, a naturally occurring calpain inhibitor, were protective.

240 This effect was also seen with other calpain inhibitors with different mechanisms of action b

241 As nanomolar calpain inhibitors with promising selectivity and low to

242 product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal

243 Some compounds acted as specific calpain inhibitors, with comparable activity on both cal

244 therefore hypothesized that treatment with a calpain inhibitor would protect neurons from immune-medi

245 e inhibited by the dipeptide alpha-ketoamide calpain inhibitor Z-Leu-aminobutyric acid-CONH(CH(2))3-m

246 Six animals were administered calpain inhibitor (Z-Leu-Leu-Tyr-fluoromethyl ketone; 1

247 itor), N-acetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-fmk (a pan-caspase inhibitor),

248 Calpain inhibitors ZLLYCHN2, MDL 28170, and PD 150606 bl